Back to Search Start Over

Differential microRNA expression in the SH-SY5Y human cell model as potential biomarkers for Huntington's disease.

Authors :
Belkozhayev A
Niyazova R
Kamal MA
Ivashchenko A
Sharipov K
Wilson CM
Source :
Frontiers in cellular neuroscience [Front Cell Neurosci] 2024 Jul 10; Vol. 18, pp. 1399742. Date of Electronic Publication: 2024 Jul 10 (Print Publication: 2024).
Publication Year :
2024

Abstract

Huntington's disease (HD) is caused by an expansion of CAG trinucleotide repeat in the HTT gene; the exact pathogenesis of HD currently remains unclear. One of the promising directions in the study of HDs is to determine the molecular mechanism underlying the development and role of microRNAs (miRNAs). This study aimed to identify the profile of miRNAs in an HD human cell line model as diagnostic biomarkers for HD. To study HD, the human SH-SY5Y HD cell model is based on the expression of two different forms: pEGFP-Q23 and pEGFP-Q74 of HTT. The expression of Htt protein was confirmed using aggregation assays combined with immunofluorescence and Western blotting methods. miRNA levels were measured in SH-SY5Y neuronal cell model samples stably expressing Q23 and Q74 using the extraction-free HTG EdgeSeq protocol. A total of 2083 miRNAs were detected, and 354 (top 18 miRNAs) miRNAs were significantly differentially expressed (DE) ( p  < 0.05) in Q23 and Q74 cell lines. A majority of the miRNAs were downregulated in the HD cell model. Moreover, we revealed that six DE miRNAs target seven genes ( ATN1, GEMIN4, EFNA5 , CSMD2, CREBBP, ATXN1, and B3GNT ) that play important roles in neurodegenerative disorders and showed significant expression differences in mutant Htt (Q74) when compared to wild-type Htt (Q23) using RT-qPCR ( p  < 0.05 and 0.01). We demonstrated the most important DE miRNA-mRNA profiles, interaction binding sites, and their related pathways in HD using experimental and bioinformatics methods. This will allow the development of novel diagnostic strategies and provide alternative therapeutic routes for treating HD.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Belkozhayev, Niyazova, Kamal, Ivashchenko, Sharipov and Wilson.)

Details

Language :
English
ISSN :
1662-5102
Volume :
18
Database :
MEDLINE
Journal :
Frontiers in cellular neuroscience
Publication Type :
Academic Journal
Accession number :
39049823
Full Text :
https://doi.org/10.3389/fncel.2024.1399742